Journal DOI 10.68956/journal.human-performance-futures

Creative Commons source reading · Machine learning for performance

Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction

Brlek P; Kolić J; Bulić L; Škaro V; Primorac D

Originally published in Front Genet · 2026-07-29

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

AbstractPeptide-based cancer vaccines represent a promising immunotherapeutic strategy aimed at inducing tumor-specific immune responses through the targeting of tumor-associated antigens and neoantigens. Recent advances in next-generation sequencing and immunogenomics have accelerated the identification of candidate neoantigens; however, the development of effective peptide vaccines remains limited by challenges related to antigen selection, HLA polymorphism, antigen processing, and variability in immunogenicity. Artificial intelligence (AI), including machine learning and deep learning approaches, has emerged as a transformative tool capable of addressing these limitations through large-scale integration and analysis of genomic, transcriptomic, proteomic, and immunological data. In this review, we summarize the current role of AI…

Conclusion

Artificial intelligence is increasingly being integrated across peptide-based cancer vaccine development, from antigen discovery and epitope prediction to patient stratification and clinical trial design. By enabling the integration and large-scale analysis of complex genomic and immunological data, AI improves the identification of clinically relevant neoantigens and accelerates vaccine development. These advances directly address key limitations that have historically constrained peptide-based strategies, particularly in antigen selection and prioritization. However, computational prediction alone is insufficient. Experimental validation of antigen processing, MHC presentation and T-cell recognition remains essential to establish biological and clinical relevance. The integration of AI-driven approaches with rigorous immunological…

Editorial reading guide

  • What data created and tested the model, and was evaluation independent?
  • What is the cost of a false positive, false negative or out-of-distribution decision?